文献速递浆细胞疾病

硼替佐米与来那度胺方案首次复发多发性骨髓瘤头对头III期研究

Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
PubMed 文献 · Br J Haematol · 2020-01-02

多发性骨髓瘤首次复发患者随机接受固定疗程VCD或RCD方案,主要终点为9周期后6周达VGPR及以上。VCD组15%、RCD组18%达VGPR及以上(P=0·70),中位PFS分别为16·3个月与18·6个月,2年OS分别为75%与74%,两方案疗效相当。

要点

  • 首次复发MM中固定疗程VCD与RCD在缓解深度、PFS和OS上疗效相当
  • VCD组VGPR及以上15%,RCD组18%,差异无统计学意义(P=0·70)
  • 两方案不良事件与已知安全性特征一致

核心结论

  • 在首次复发的多发性骨髓瘤患者中,硼替佐米方案与来那度胺方案在缓解深度、无进展生存和总生存方面疗效相当。

研究设计与样本

  • 开放标签III期随机对照研究,2011年3月至2015年2月共随机155例首次复发MM患者,比较9周期VCD与RCD固定疗程方案。
  • 主要终点为9个治疗周期后6周达到VGPR或更好缓解。

主要发现

  • VCD组12例(15%)达VGPR及以上,RCD组14例(18%),P=0·70。
  • 中位PFS:VCD组16·3个月(95%CI:12·1-22·4),RCD组18·6个月(95%CI:14·7-25·5)。
  • 2年OS:VCD组75%(95%CI:66-86%),RCD组74%(95%CI:64-85%)。
  • 亚组分析中,硼替佐米和来那度胺初治患者及一线接受硼替佐米方案者的PFS均未见差异。

关键数值与推荐

  • VGPR及以上:VCD组15%(12例)vs RCD组18%(14例),P=0·70。
  • 中位PFS:VCD组16·3个月(95%CI:12·1-22·4)vs RCD组18·6个月(95%CI:14·7-25·5)。
  • 2年OS:VCD组75%(95%CI:66-86%)vs RCD组74%(95%CI:64-85%)。

临床怎么用

  • 首次复发MM选择固定疗程VCD或RCD均可,需结合既往用药与安全性个体化决定。
  • 既往未用过硼替佐米或来那度胺者及一线含硼替佐米者,两方案PFS均无差异。

局限性

  • 样本量155例,两组缓解率比较的统计效能有限。
  • 开放标签设计可能影响不良事件评估;具体不良事件数据未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bortezomib- and lenalidomide-containing regimens are well-established therapies in multiple myeloma (MM). However, despite their extensive use, head-to-head comparisons have never been performed. Therefore, we compared bortezomib and lenalidomide in fixed-duration therapies. In this open-label, phase III study, we randomized MM patients at first relapse to receive either nine cycles of bortezomib plus cyclophosphamide plus dexamethasone (VCD) or lenalidomide plus cyclophosphamide plus dexamethasone (RCD). The primary endpoint was achievement of a very good partial response (VGPR) or better at six weeks after nine treatment cycles. From March 2011 to February 2015, 155 patients were randomized. VGPR or better was achieved by 12 patients (15%) in the VCD arm and 14 patients (18%) in the RCD arm (P = 0·70). Median progression-free survival (PFS) was 16·3 (95% CI: 12·1-22·4) with VCD and 18·6 months (95% CI: 14·7-25·5) with RCD, and the two-year overall survival (OS) was 75% (95% CI: 66-86%) and 74% (95% CI: 64-85%) respectively. In subgroup analyses, no differences in PFS were observed in bortezomib- and lenalidomide-naïve patients, nor in patients who received a bortezomib-based regimen in first line. Adverse events were consistent with the well-established safety profiles of both drugs. Bortezomib and lenalidomide treatments were equally effective in terms of depth of response, PFS, and OS in MM patients at first relapse.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Montefusco V, Corso A, Galli M, et al. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. Br J Haematol. 2020. PMID: 31898319. doi:10.1111/bjh.16287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。